2024-11-13 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**1. Performance Comparison:**

Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a diverse range of healthcare products, including pharmaceuticals, medical devices, nutrition products, and diagnostics. 

ABT has generated a cumulative return of 143.35% compared to the S&P 500's (VOO) cumulative return of 179.25%. This translates to a **-35.9% performance gap**. However, considering the historical range of the performance gap (91.67% to -50.36%), ABT currently sits in the **10.18th percentile**, suggesting it has underperformed the S&P 500 historically but currently is not significantly trailing. 

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 36.2% | 23.4% | -2.2% | 1.1 | 99.0 |
| 2016-2018  | 80.0% | 14.7% | 47.7% | 1.1 | 125.5 |
| 2017-2019  | 135.6% | 11.7% | 83.9% | 1.1 | 150.7 |
| 2018-2020  | 95.8% | 31.2% | 48.5% | 0.9 | 189.9 |
| 2019-2021  | 112.3% | 31.2% | 12.3% | 0.8 | 244.1 |
| 2020-2022  | 32.4% | 31.2% | 8.8% | 0.8 | 190.4 |
| 2021-2023  | 6.2% | 30.6% | -28.7% | 0.7 | 190.9 |
| 2022-2024  | -11.4% | 29.6% | -41.8% | 0.7 | 202.6 |

ABT generally exhibits a beta slightly above 1, indicating that it tends to move in line with the broader market but with slightly higher volatility. Alpha, however, shows a mixed performance, with periods of both positive and negative outperformance.

**2. Recent Price Action:**

| Indicator           | Value |
|--------------------|-------|
| Closing Price      | 116.44 |
| 5-Day Moving Average | 116.39 |
| 20-Day Moving Average | 116.36 |
| 60-Day Moving Average | 114.61 |

The price of ABT is trading slightly above its 5-day and 20-day moving averages, suggesting short-term bullish momentum. However, the price is still below its 60-day moving average, implying a potential longer-term downtrend.

**3. Technical Indicators:**

| Indicator                               | Value | Interpretation                                            |
|-----------------------------------------|-------|-----------------------------------------------------|
| Relative Strength Index (RSI)          | 48.25 | Neutral, neither overbought nor oversold                  |
| Price Oscillator (PPO)                | -0.03 | Slight bearish signal, but close to neutral territory |
| Delta_Previous_Relative_Divergence    | -4.99 | Short-term downward momentum                             |
| Expected Return (vs. S&P 500, 2+ years) | 0.0%  |  No significant expected outperformance             |

The technical indicators suggest a neutral to slightly bearish short-term outlook.  The price is currently approaching the 60-day moving average, which could potentially serve as a resistance level.

**4. Recent Earnings and Outlook:**

| Date          | EPS     | Revenue     |
|---------------|---------|-------------|
| 2024-10-31   | 0.94    | 10.63 B$   |
| 2024-07-31   | 0.74    | 10.38 B$   |
| 2024-05-02   | 0.70    | 9.96 B$    |
| 2023-11-01   | 0.82    | 10.14 B$   |
| 2024-10-31   | 0.82    | 10.14 B$   |

The latest reported EPS for Q3 2024 of $0.94 beat analyst expectations by $0.08. This indicates positive momentum in the business. 

**5. Financial Data:**

**1) Revenue and Profitability:**

| Quarter       | Revenue   | Profit Margin |
|---------------|-----------|---------------|
| 2024-09-30   | $10.63B  | 55.83%        |
| 2024-06-30   | $10.38B  | 55.64%        |
| 2024-03-31    | $9.96B   | 55.21%        |
| 2023-12-31   | $10.24B  | 55.51%        |
| 2023-09-30   | $10.14B  | 54.60%        |

ABT demonstrates a steady growth in revenue and maintains a healthy profit margin, indicating robust financial health.

**2) Capital and Profitability:**

| Quarter       | Equity   | ROE |
|---------------|----------|-----|
| 2024-09-30   | $39.80B | 4.14% |
| 2024-06-30   | $39.32B | 3.31% |
| 2024-03-31    | $38.81B | 3.16% |
| 2023-12-31   | $38.60B | 4.13% |
| 2023-09-30   | $37.48B | 3.83% |

ABT has consistently maintained a strong capital position with a solid ROE. The company is clearly committed to shareholder value.

**6. News and Recent Events:**

* **Recent Earnings:** ABT beat earnings estimates in the latest quarter, signaling strong performance and positive investor sentiment.
* **Market Outlook:** FINBOLD analysts suggest that ABT is poised for continued growth, with the company's focus on innovation and expansion in key markets expected to drive positive returns.
* **Analyst Opinions:** According to various sources, ABT holds a consensus "Buy" rating from analysts, with an average price target that indicates potential upside from current levels.

**7. Summary and Conclusion:**

ABT is a financially strong company with a history of steady growth and innovation. Recent earnings performance has been positive, and analysts remain bullish on the stock's long-term prospects. However, the company has historically lagged the S&P 500, and current technical indicators suggest some short-term bearish sentiment. Overall, ABT presents an attractive investment opportunity for investors seeking exposure to the healthcare sector, but its long-term performance against the broader market remains to be seen.

**Disclaimer:** This report is for informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence before making any investment decisions.
